Chronic Pulmonary Hypertension
&nbsp;
Pulmonary hypertension encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance. Pulmonary hypertension is a progressive disease with treatment focused on the management of symptoms and treatment of underlying diseases.
Some common underlying causes of pulmonary hypertension include high blood pressure in the lungs&rsquo; arteries due to some types of congenital heart disease, connective tissue disease, coronary artery disease, high blood pressure, liver disease (cirrhosis), blood clots to the lungs, and chronic lung diseases like emphysema. Genetics also plays a role.
&nbsp;
Chronic Pulmonary Hypertension Epidemiology Segmentation in the 7MM
&nbsp;
<ul>
<li class="ql-align-justify">&nbsp;Total Prevalent Cases of Chronic Pulmonary Hypertension</li>
<li class="ql-align-justify"> Group-specific prevalent cases of Chronic Pulmonary Hypertension</li>
<li class="ql-align-justify"> Gender-specific prevalent cases of Chronic Pulmonary Hypertension</li>
<li class="ql-align-justify">Age-specific prevalent cases of Chronic Pulmonary Hypertension</li>
</ul>
&nbsp;
&nbsp;
<a style="color: #1155cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/chronic-pulmonary-hypertension-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Chronic Pulmonary Hypertension Epidemiological Insights Observed in the 7MM (2021)</a>
&nbsp;
<ul>
<li class="ql-align-justify">The total incident cases of Chronic Pulmonary Hypertension observed in the 7MM were observed to be 42 million in the year 2021</li>
</ul>
&nbsp;
<a style="color: #1155cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/chronic-pulmonary-hypertension-market" target="_blank" rel="noopener noreferrer">Chronic Pulmonary Hypertension Market Insight</a>
&nbsp;
The market size of Chronic Pulmonary Hypertension in the 7MM was found to be approximately USD 26,500 million in 2021. &nbsp;
&nbsp;
Chronic Pulmonary Hypertension Emerging Drugs
&nbsp;
The emerging drugs in the Chronic Pulmonary Hypertension market are
<ul>
<li class="ql-align-justify"> Supernitro (PDNO)</li>
<li class="ql-align-justify">CS1</li>
<li class="ql-align-justify">Zamicastat (BIA 5-1058)</li>
<li class="ql-align-justify">YUTREPIA (LIQ861 Inhaled Treprostinil)</li>
<li class="ql-align-justify">INOpulse&reg; A</li>
<li class="ql-align-justify">&nbsp;Levosimendan</li>
<li class="ql-align-justify">Treprostinil palmitil</li>
<li class="ql-align-justify">Rodatristat Ethyl and others</li>
</ul>
&nbsp;
Chronic Pulmonary Hypertension Key Players&nbsp;
&nbsp;
The key players working in the Chronic Pulmonary Hypertension market are
&nbsp;
<ul>
<li class="ql-align-justify">Attgeno AB</li>
<li class="ql-align-justify">Cereno Scientific AB</li>
<li class="ql-align-justify">Liquidia Technologies</li>
<li class="ql-align-justify">Bial - Portela C S.A</li>
<li class="ql-align-justify">Bellerophon Therapeutics</li>
<li class="ql-align-justify">AbbVie</li>
<li class="ql-align-justify">Tenax Therapeutics</li>
<li class="ql-align-justify">Insmed</li>
<li class="ql-align-justify">Altavant Sciences and others</li>
</ul>

Chronic Pulmonary Hypertension Market

Chronic Pulmonary Hypertension

 Chronic Pulmonary Hypertensione Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape